DIAJARD M 12.5/500MG TABLET

DIAJARD M 12.5/500MG Tablet is a combination medication that contains two active ingredients: empagliflozin and metformin. Empagliflozin belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, while metformin is a member of the biguanide class of antidiabetic medications. This combination is used to treat type 2 diabetes mellitus in adults to help control blood sugar levels.

Uses:

1. Type 2 Diabetes Mellitus Management: DIAJARD M Tablet is primarily prescribed to manage type 2 diabetes in adult patients. It helps control blood glucose levels by reducing the amount of sugar reabsorbed by the kidneys and increasing the excretion of glucose through urine. Metformin works by decreasing glucose production in the liver and improving insulin sensitivity, thereby aiding in better glycemic control.

Side Effects:

Like all medications, DIAJARD M 12.5/500MG Tablet may cause some side effects in some individuals. Not everyone will experience these side effects, and they may vary in severity. Common side effects of this combination may include:

1. Urinary Tract Infections (UTIs): Empagliflozin’s mechanism of action involves increasing glucose excretion in the urine, which may lead to an increased risk of UTIs.
2. Genital Infections: Some patients may experience genital yeast infections due to the increased sugar content in the genital area caused by empagliflozin.
3. Hypoglycemia: Though less common with metformin, combining it with empagliflozin may increase the risk of hypoglycemia (low blood sugar levels). This risk is higher if the medication is used in combination with other antidiabetic drugs.
4. Gastrointestinal Disturbances: Nausea, diarrhea, vomiting, and abdominal discomfort may occur in some patients.
5. Dehydration: Empagliflozin can lead to increased urination and potential dehydration, particularly in elderly patients or those with pre-existing kidney problems.
6. Lactic Acidosis: Although rare, metformin has been associated with a serious condition called lactic acidosis, characterized by an accumulation of lactic acid in the blood. Seek immediate medical attention if you experience symptoms such as weakness, fatigue, muscle pain, irregular heartbeat, or difficulty breathing.

When Not to Use:

1. Type 1 Diabetes: DIAJARD M 12.5/500MG Tablet is not indicated for the treatment of type 1 diabetes.
2. Diabetic Ketoacidosis (DKA): This medication should not be used in patients with diabetic ketoacidosis, a serious condition characterized by high ketone levels in the blood.
3. Severe Kidney Impairment: Individuals with severe kidney impairment or end-stage renal disease should avoid using this medication due to the risk of lactic acidosis.
4. Allergy or Hypersensitivity: If you have a known allergy or hypersensitivity to empagliflozin, metformin, or any other components of the tablet, you should not use DIAJARD M.
5. Severe Liver Dysfunction: Patients with severe liver problems should avoid this medication as it can exacerbate the condition.
6. During Pregnancy and Breastfeeding: The safety of DIAJARD M during pregnancy and breastfeeding has not been established. Consult your doctor before using this medication if you are pregnant or breastfeeding.

Always follow your healthcare provider’s instructions and never self-medicate. If you experience any severe or persistent side effects, contact your doctor immediately.